Literature DB >> 2653395

Joint pain and quality of life; results of a randomised trial.

G Parr1, B Darekar, A Fletcher, C J Bulpitt.   

Abstract

1. Eight hundred and forty-six patients with pain in one or two joints of the hip, knee, ankle or wrist participated in a randomised double-blind trial to compare the efficacy, tolerability and effect on quality of life of diclofenac sodium slow release (DSR) 100 mg daily and a combination of dextropropoxyphene 180 mg and paracetamol 1.95 g daily (D&P). Health status or quality of life was measured using the Nottingham Health Profile (NHP) questionnaire. 2. Pain as measured by a visual analogue scale (VAS) showed 8% greater pain reduction with DSR as compared with D&P (P less than 0.05). Physical mobility as measured by the NHP improved by 13% more with DSR as compared with D&P (P less than 0.01). Energy, sleep, social isolation and emotional reactions did not differ significantly between the two treatment groups, but both treatment groups showed improvement during the trial. More D&P patients as compared with DSR patients reported problems with their job of work (P less than 0.05), and time lost from work (P less than 0.05). 3. Patients on D&P suffered an excess of tiredness or sleep disturbance (50 vs 21, P less than 0.01) whilst patients treated with DSR had an excess of abdominal or epigastric pain or indigestion (40 vs 18, P less than 0.01). 57 patients were withdrawn from DSR and 65 from D&P.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2653395      PMCID: PMC1379785          DOI: 10.1111/j.1365-2125.1989.tb05356.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  A comparison of normal and pathological synovial fluid.

Authors:  F Fawthrop; J Hornby; A Swan; C Hutton; M Doherty; P Dieppe
Journal:  Br J Rheumatol       Date:  1985-02

2.  Biochemical and histological changes in osteoarthritic synovial membrane.

Authors:  O Gedikoglu; M T Bayliss; S Y Ali; I Tuncer
Journal:  Ann Rheum Dis       Date:  1986-04       Impact factor: 19.103

3.  The Norwegian multicenter study.

Authors:  G Husby
Journal:  Am J Med       Date:  1986-11-28       Impact factor: 4.965

4.  Measuring health status: a new tool for clinicians and epidemiologists.

Authors:  S M Hunt; J McEwen; S P McKenna
Journal:  J R Coll Gen Pract       Date:  1985-04

5.  Analogue chromatic continuous scale (ACCS): a new method for pain assessment.

Authors:  E Grossi; C Borghi; E L Cerchiari; T Della Puppa; B Francucci
Journal:  Clin Exp Rheumatol       Date:  1983 Oct-Dec       Impact factor: 4.473

6.  Subjective health of patients with peripheral vascular disease.

Authors:  S M Hunt; J McEwen; S P McKenna; E M Backett; C U Pope
Journal:  Practitioner       Date:  1982-01

7.  Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial.

Authors:  C Bombardier; J Ware; I J Russell; M Larson; A Chalmers; J L Read
Journal:  Am J Med       Date:  1986-10       Impact factor: 4.965

8.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

9.  Reliability of a population survey tool for measuring perceived health problems: a study of patients with osteoarthrosis.

Authors:  S M Hunt; S P McKenna; J Williams
Journal:  J Epidemiol Community Health       Date:  1981-12       Impact factor: 3.710

  9 in total
  15 in total

Review 1.  EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; N Arden; B Bannwarth; J Bijlsma; K-P Gunther; H J Hauselmann; G Herrero-Beaumont; K Jordan; P Kaklamanis; B Leeb; M Lequesne; S Lohmander; B Mazieres; E Martin-Mola; K Pavelka; A Pendleton; L Punzi; B Swoboda; R Varatojo; G Verbruggen; I Zimmermann-Gorska; M Dougados
Journal:  Ann Rheum Dis       Date:  2004-10-07       Impact factor: 19.103

2.  Measurement of the quality of life in clinical trials: in pursuit of the unapproachable?

Authors:  L Offerhaus
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  The treatment of osteoarthritis.

Authors:  A C Jones; M Doherty
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

4.  North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group.

Authors:  M Eccles; N Freemantle; J Mason
Journal:  BMJ       Date:  1998-08-22

Review 5.  Quality of life as an outcome measure.

Authors:  C J Bulpitt
Journal:  Postgrad Med J       Date:  1997-10       Impact factor: 2.401

Review 6.  Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  H A Wynne; M Campbell
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

7.  Health-related quality of life in patients with insomnia treated with zopiclone.

Authors:  D Leger; M A Quera-Salva; P Philip
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

8.  Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation.

Authors:  R E Johnson; M C Hornbrook; R S Hooker; G T Woodson; R Shneidman
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

Review 9.  A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain.

Authors:  Andrea Furlan; Luis E Chaparro; Emma Irvin; Angela Mailis-Gagnon
Journal:  Pain Res Manag       Date:  2011 Sep-Oct       Impact factor: 3.037

10.  Individual-patient monitoring in clinical practice: are available health status surveys adequate?

Authors:  C A McHorney; A R Tarlov
Journal:  Qual Life Res       Date:  1995-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.